Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatinib treatment of progenitor cells from chronic-phase CML patients for 4 hours, followed by washout, or continuously for 72 hours both resulted in an induction of apoptosis and a reduction in the number of clonogenic cells. Such acute treatments with clinically achievable dasatinib concentrations also irreversibly committed Bcr-Abl+ CML cell lines to apoptotic cell death. Potent transient Bcr-Abl inhibition using the alternative inhibitor, nilotinib, also resulted in cell death. These findings demonstrate that in vitro assays designed to model in vivo pharmacokinetics can predict clinical efficacy. Furthermore, they challenge the widely held notion that continuous target inhibition is required for optimal efficacy of kinase inhibitors.
Snead
Jennifer L
JL
Division of Hematology & Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239, USA.
O'Hare
Thomas
T
Adrian
Lauren T
LT
Eide
Christopher A
CA
Lange
Thoralf
T
Druker
Brian J
BJ
Deininger
Michael W
MW
D017209:Apoptosis / Q000187:drug effects*; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology; D014411:Neoplastic Stem Cells / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib
Science. 1990 Mar 2;247(4946):1079-82
2408149
Cancer Cell. 2005 Feb;7(2):129-41
15710326
Cancer Res. 2006 Jun 1;66(11):5790-7
16740718
Science. 1990 Feb 16;247(4944):824-30
2406902
Blood. 1994 Nov 1;84(9):2912-8
7524758
Oncogene. 1997 Feb 6;14(5):507-13
9053848
Cancer Res. 1996 Jan 1;56(1):100-4
8548747
Cancer Res. 2005 Jun 1;65(11):4500-5
15930265
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Science. 2000 Sep 15;289(5486):1938-42
10988075
Blood. 1994 Sep 15;84(6):1731-6
7521685
Blood. 2006 Jun 1;107(11):4532-9
16469872
Science. 2004 Jul 16;305(5682):399-401
15256671
Cancer Cell. 2008 Dec 9;14(6):485-93
19061839
Nature. 1973 Jun 1;243(5405):290-3
4126434
Blood. 2007 Dec 1;110(12):4055-63
17720881
Blood. 2007 Apr 15;109(8):3496-9
17192396
Cancer Cell. 2004 Mar;5(3):287-98
15050920
J Clin Oncol. 2008 Jul 1;26(19):3204-12
18541900
Blood. 2007 Jun 15;109(12):5143-50
17317857
J Natl Cancer Inst. 1999 Jan 20;91(2):163-8
9923858
Blood. 2008 Apr 15;111(8):4022-8
18256322
Clin Cancer Res. 2006 Dec 1;12(23):7180-6
17145844
Blood. 2007 May 1;109(9):4006-15
17218385
J Biol Chem. 1994 Sep 16;269(37):22925-8
8083188
Cancer Cell. 2006 Nov;10(5):425-35
17097564
Nat Med. 1996 May;2(5):561-6
8616716
Blood. 2002 Jan 15;99(2):664-71
11781252
Antimicrob Agents Chemother. 1995 Mar;39(3):650-5
7793867
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S95-S106
19254887
J Clin Oncol. 2004 Mar 1;22(5):935-42
14990650
N Engl J Med. 2006 Jun 15;354(24):2542-51
16775235
J Clin Oncol. 2007 Oct 1;25(28):4445-51
17906206